Related references
Note: Only part of the references are listed.Differences in persistence among different weekly oral bisphosphonate medications
O. Sheehy et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data
A. Cranney et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures
O. Sheehy et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Excess mortality following hip fracture: a systematic epidemiological review
B. Abrahamsen et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis
Fernie J. A. Penning-van Beest et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures
Willemijn M. Meijer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Epidemiology of distal forearm fractures in Oslo, Norway
C. M. Lofthus et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies
Steven T. Harris et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Consequences of poor compliance with bisphosphonates
Becky A. Briesacher et al.
BONE (2007)
Zoledronic acid and clinical fractures and mortality after hip fracture
Kenneth W. Lyles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate
Michael McClung et al.
BONE (2007)
Non-compliance:: the Achilles' heel of anti-fracture efficacy
E. Seeman et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density
Kenneth Saag et al.
BONE (2007)
Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study
C. H. A. van den Boogaard et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases
Ethel S. Siris et al.
MAYO CLINIC PROCEEDINGS (2006)
The cost-effectiveness of risedronate in the treatment of osteoporosis:: an international perspective
F. Borgstrom et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Cost-effectiveness of alternative treatments for women with osteoporosis in Canada
Ron Goeree et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Incidence and costs of injuries in The Netherlands
Willem Jan Meerding et al.
EUROPEAN JOURNAL OF PUBLIC HEALTH (2006)
Persistence with weekly alendronate therapy among postmenopausal women
J. C. Lo et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Assessment of compliance with osteoporosis treatment and its consequences in a managed care population
KF Huybrechts et al.
BONE (2006)
Costs and quality of life associated with osteoporosis-related fractures in Sweden
F Borgström et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women
JT Schousboe et al.
ANNALS OF INTERNAL MEDICINE (2005)
Requirements for DXA for the management of osteoporosis in Europe
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Excess mortality after hospitalisation for vertebral fracture
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2004)
A meta-analysis of previous fracture and subsequent fracture risk
JA Kanis et al.
BONE (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Consequences of hip fracture on activities of daily life and residential needs
EK Osnes et al.
OSTEOPOROSIS INTERNATIONAL (2004)
The risk and burden of vertebral fractures in Sweden
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Cost effectiveness of alendronate (Fosamax (R)) for the treatment of osteoporosis and prevention of fractures
O Johnell et al.
PHARMACOECONOMICS (2003)
Cost analysis of hip fracture treatment among the elderly for the public health services: a 1-year prospective study in 106 consecutive patients
I Nurmi et al.
ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY (2003)
International variations in hip fracture probabilities: Implications for risk assessment
JA Kanis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Epidemiology of hip fractures in Oslo, Norway
CM Lofthus et al.
BONE (2001)
Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis
CM Klotzbuecher et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Long-term risk of osteoporotic fracture in Malmo
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Risk of mortality following clinical fractures
JA Cauley et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
